Long-term Givlaari for AHP Found to Ease Pain, Lessen Attack Rate

Long-term Givlaari for AHP Found to Ease Pain, Lessen Attack Rate

311732

Long-term Givlaari for AHP Found to Ease Pain, Lessen Attack Rate

Long-term treatment with Givlaari (givosiran) lessens rates of porphyria attacks, eases pain, and improves quality of life in individuals with acute hepatic porphyria (AHP), according to two-year interim data from the ENVISION trial. Results were reported in the study, “Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study,” published in the journal Liver International. The research was funded by Givlaari’s developer, Alnylam Pharmaceuticals. AHP includes…

You must be logged in to read/download the full post.